Cargando…

Optimal loading dose of meropenem before continuous infusion in critically ill patients: a simulation study

The aim of this study was to investigate optimal loading doses prior to continuous infusion of meropenem in critically ill patients. A previously published and successfully evaluated pharmacokinetic model of critically ill patients was used for stochastic simulations of virtual patients. Maintenance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liebchen, Uwe, Salletmeier, Hanna, Kallee, Simon, Scharf, Christina, Huebner, Lucas, Weber, Alexandra, Zoller, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390684/ https://www.ncbi.nlm.nih.gov/pubmed/34446780 http://dx.doi.org/10.1038/s41598-021-96744-3

Ejemplares similares

No clinically relevant removal of meropenem by cytokine adsorber CytoSorb(®) in critically ill patients with sepsis or septic shock
por: Liebchen, Uwe, et al.
Publicado: (2021)

Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
por: Schatz, Lea Marie, et al.
Publicado: (2023)

Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness—Experience and Recommendations from One Year in Routine Clinical Practice
por: Scharf, Christina, et al.
Publicado: (2020)

Continuous infusion of meropenem in critically ill patients: practical considerations
por: Taccone, Fabio Silvio
Publicado: (2012)

Systematic Evaluation of Voriconazole Pharmacokinetic Models without Pharmacogenetic Information for Bayesian Forecasting in Critically Ill Patients
por: Kallee, Simon, et al.
Publicado: (2022)

Meropenem: continuous or extended infusion?
por: Frippiat, Frédéric, et al.
Publicado: (2020)

The Role of Non-Enzymatic Degradation of Meropenem—Insights from the Bottle to the Body
por: Liebchen, Uwe, et al.
Publicado: (2021)

Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients
por: Liebchen, Uwe, et al.
Publicado: (2021)

Continuous infusion versus intermittent administration of meropenem in critically ill patients: a pilot study
por: Thalhammer, F, et al.
Publicado: (1999)

Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients
por: Luque, Sonia, et al.
Publicado: (2021)

The cytokine adsorber Cytosorb® does not reduce ammonia concentrations in critically ill patients with liver failure
por: Liebchen, Uwe, et al.
Publicado: (2023)

Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis
por: Scharf, Christina, et al.
Publicado: (2021)

Therapeutic drug monitoring-guided high dose meropenem therapy of a multidrug resistant Acinetobacter baumannii - A case report
por: Liebchen, U., et al.
Publicado: (2019)

Software- and TDM-Guided Dosing of Meropenem Promises High Rates of Target Attainment in Critically Ill Patients
por: Chiriac, Ute, et al.
Publicado: (2023)

Meropenem administration by intermittent infusion versus continuous infusion for the treatment of nosocomial pneumonia
por: Lorente, L, et al.
Publicado: (2005)

Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial
por: Benítez-Cano, Adela, et al.
Publicado: (2020)

402 Pharmacokinetics of Extended vs Intermittent Intravenous Infusion of Meropenem in Critically Ill Patients Receiving Continuous Veno-Venous Haemofiltration
por: Frippiat, Frédéric, et al.
Publicado: (2014)

Can the cytokine adsorber CytoSorb(®) help to mitigate cytokine storm and reduce mortality in critically ill patients? A propensity score matching analysis
por: Scharf, Christina, et al.
Publicado: (2021)

Continuous Infusions of Meropenem in Ambulatory Care: Clinical Efficacy, Safety and Stability
por: Manning, Laurens, et al.
Publicado: (2014)

Was ist neu … in der Behandlung von invasiven Mykosen. COVID-19-assoziierte pulmonale Aspergillose
por: Scharf, Christina, et al.
Publicado: (2021)

The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome
por: Scharf, Christina, et al.
Publicado: (2020)

Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study
por: Scharf, Christina, et al.
Publicado: (2021)

Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis
por: Pařízková, Renata Černá, et al.
Publicado: (2021)

Therapeutic drug monitoring of meropenem and piperacilin administered in continuous infusion. preliminary data
por: Miralbés Torner, M, et al.
Publicado: (2015)

Clearance of meropenem during continuous renal replacement therapy in critically ill patients
por: Thalhammer, F, et al.
Publicado: (1999)

Pharmacokinetics of meropenem during continuous renal replacement therapy in critically ill patients
por: Solé Violan, J, et al.
Publicado: (2014)

Continuous infusion of meropenem–vaborbactam for a KPC-3-producing Klebsiella pneumoniae bloodstream infection in a critically ill patient with augmented renal clearance
por: Larcher, Romaric, et al.
Publicado: (2023)

The effect of cytosorb® application on kidney recovery in critically ill patients with severe rhabdomyolysis: a propensity score matching analysis
por: Gräfe, Caroline, et al.
Publicado: (2023)

Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis
por: Yu, Zhenwei, et al.
Publicado: (2018)

Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study
por: Scharf, Christina, et al.
Publicado: (2022)

An investigation of the stability of meropenem in elastomeric infusion devices
por: Foy, Finbarr, et al.
Publicado: (2019)

Continuous Vancomycin Infusion versus Intermittent Infusion in Critically Ill Patients
por: Maluangnon, Chailat, et al.
Publicado: (2022)

Cerebrospinal Fluid Concentrations of Meropenem and Vancomycin in Ventriculitis Patients Obtained by TDM-Guided Continuous Infusion
por: Tiede, Christoph, et al.
Publicado: (2021)

Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients
por: Zhao, Yi-Chang, et al.
Publicado: (2021)

Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion
por: Venugopalan, Veena, et al.
Publicado: (2018)

Meropenem pharmacokinetics in critically ill patients with or without burn treated with or without continuous veno‐venous haemofiltration
por: Selig, Daniel J., et al.
Publicado: (2021)

Pharmacokinetics of meropenem in critically ill patients in Saudi Arabia
por: Alsultan, Abdullah, et al.
Publicado: (2021)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients
por: Gan, Yuhong, et al.
Publicado: (2023)

Measuring Creatinine Clearance Is the Most Accurate Way for Calculating the Proper Continuous Infusion Meropenem Dose for Empirical Treatment of Severe Gram-Negative Infections among Critically Ill Patients
por: Troisi, Carla, et al.
Publicado: (2023)

Early Target Attainment With Continuous Infusion Meropenem and Piperacillin/Tazobactam and Utilization of Therapeutic Drug Monitoring in Critically Ill Patients: A Retrospective Cohort Study From 2017 to 2020
por: Dräger, Sarah, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gs4j9bbv74uibf6ng3demb66uj